Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback